Evidence map›Paper›PMID 42838965›Full record

Observational studyNature communications2026

Rapid Whole Genome Sequencing Enhances Pediatric Cancer Diagnosis.

Aditi Vedi, Jamie Trotman, Joao M L Dias, Martina Mijuskovic, Sera Choi, Laura Kingham, Rachel A Moore, Sarah M Leiter, Rowena Guermech, Amanda Semerene and 30 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07201038 (Feasibility of Ultrafast WGS in Paediatric Malignancies), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07201038 recruitingnot on this map

Feasibility of Ultrafast WGS in Paediatric Malignancies

TypeobservationalSponsorUniversity of CambridgeRan2022 to 2028Enrolled50ConditionsCancer Childhood
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Aditi VediCambridge University Hospitals NHS Foundation Trust, Cambridge, UK. av448@cam.ac.uk.ORCID 0000-0001-6761-6510
Jamie Trotman *Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-6246-4121
Joao M L Dias *University of Cambridge, Department of Paediatrics, Cambridge, UK.ORCID 0000-0002-8451-3537
Martina MijuskovicIllumina Inc., Cambridge, UK.
Sera ChoiIllumina Inc., Cambridge, UK.
Laura KinghamCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Rachel A MooreCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Sarah M LeiterCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0001-8321-3260
Rowena GuermechCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Amanda SemereneCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Aviva GrisbyCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Sophie WoolCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Victoria JoslinCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Arunthethy MahendrayogamCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Jonathan AbramsCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-4044-6969
Michael GattensCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Esther BlancoCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Emmy L DickensCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Charlotte BurnsCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Matthew J MurrayCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-4480-1147
John A TadrossCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-8424-1252
Claire TrayersCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Catherine E HookCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-0450-7656
Jennifer BecqIllumina Inc., Cambridge, UK.
Taksina NewingtonIllumina Inc., Cambridge, UK.
Ivana ArmogidaIllumina Inc., Cambridge, UK.
Zoya KingsburyIllumina Inc., Cambridge, UK.
Pascal GrobeckerIllumina Inc., Cambridge, UK.ORCID 0009-0001-8339-4775
Ines VitorianoIllumina Inc., Cambridge, UK.
Mitchell A BekritskyIllumina, Inc., San Diego, CA, USA.
Jacqueline WeirIllumina Inc., Cambridge, UK.
Louise J FraserIllumina Inc., Cambridge, UK.ORCID 0000-0001-9709-6827
Mark RossIllumina Inc., Cambridge, UK.
David BentleyIllumina Inc., Cambridge, UK.
Matthew CullenCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Sam BehjatiCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-6600-7665
Jack BartramGreat Ormond Street Hospital, London, UK.
Sean J HumphrayIllumina Inc., Cambridge, UK.
Patrick TarpeyCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-2042-4543
David RowitchCambridge University Hospitals NHS Foundation Trust, Cambridge, UK. dhr25@cam.ac.uk.ORCID 0000-0002-0079-0060

Funding

Rosetrees Trust CF-2023-I-2\104Wellcome TrustWellcome Trust (Wellcome) 312471/Z/24/Z
6 · The paper itself

Abstract

Whole-genome sequencing (WGS) has been shown to improve diagnosis beyond standard-of-care genetic tests and guide precision treatment for childhood cancer. While WGS is now offered for children with suspected cancer in England, clinical workflows typically return results after several weeks whereas clinical decisions are often required within days. Here we evaluate feasibility and efficacy of a rapid WGS (rWGS) research workflow with streamlined bioinformatics to deliver clinical genomic findings (NCT07201038, Active, not recruiting). In 54 children with suspected or confirmed malignancy, rWGS reduces mean end-to-end turnaround time from 42 to 3 days, whilst increase variant detection rate. Whereby rWGS detected 147 of 155 (95%) clinically actionable variants identified in the cohort, standard of care testing detected 138 of 155 (89%) variants. In a subset of 35 patients assessed prospectively, clinicians report that in 17 (49%), rWGS either (i) facilitates faster access to targeted therapy and risk stratification, or (ii) avoids unnecessary investigations and treatment escalation. These findings indicate feasibility and suggest clinical utility of rWGS when deployed as a first line diagnostic test in pediatric oncology.

Indexed as

NeoplasmsWhole Genome SequencingAdolescentChildChild, PreschoolFemaleGenetic TestingHumansInfantMaleProspective Studies

Identifiers

PMID42838965
PMCPMC13642919

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.